BRIM Biotech submits US Phase 3 clinical trial protocol for BRM421 in the treatment of dry eye disease to the FDA
Taipei, Taiwan, Nov 16th, 2022, BRIM Biotechnology, Inc. (“BRIM,” TPEx 6885) announced today that it has officially submitted the Phase 3 clinical trial protocol for BRM421 in the treatment of dry eye disease (DED) to the U.S. Food and Drug Administration…
BRIM Biotechnology receives FDA agreement on Phase 3 clinical trial design for BRM421, BRIM’s lead candidate for Dry Eye Disease, at End of Phase 2 Meeting
Taipei, Taiwan, 1st November, 2022 / BRIM Biotechnology, Inc. (“BRIM,” TPEx 6885) is pleased to announce that it has received agreement from the US Food and Drug Administration (FDA) on the Phase 3 clinical trial design for its lead candidate…
BRIM Biotechnology Board of Directors approves seasoned equity offering of USD 18 million to accelerate phase 3 development of lead asset BRM421 for dry eye disease
Taipei, Taiwan, August 12th, 2022/ BRIM Biotechnology, Inc. (BRIM, TPEx 6885) reports that the Company’s Board of Directors has approved a proposal for a seasoned equity offering, following its recent emerging stock market (ESM) listing, to increase capital and advance…
The road to regeneration: Could regenerative peptide therapy pave the way for new treatment methods for severe dry eye?
Severe dry eye disease (DED) affects the productivity and quality of life of millions of people. Prompted by the prevalence of this chronic condition, many pharmaceutical companies have set out in search of more robust treatments. Solutions have thus far…
BRIM Biotechnology enters Emerging Stock Market in Taiwan
Taipei, Taiwan, 23 rd June 2022 / BRIM Biotechnology, Inc. (BRIM, TPEx 6885) enters the Emerging Stock Market (ESM) in Taiwan on 23 rd June 2022, CST. The news was announced at the company’s first earnings call on 22 nd…
A Team Approach to Translational Science
Success doesn’t just come from a winning idea or an exciting new concept. Success comes from having a dedicated team behind that idea, with the enthusiasm and commitment to drive it from concept to clinic. The people behind the peptide…
BRIM Biotechnology, Inc. and Ora, Inc. announce new partnership to accelerate the development of regenerative peptide therapy, BRM421 for Dry Eye Disease
Taipei, Taiwan, May 17th, 2022: BRIM Biotechnology, Inc. (“BRIM”) a clinical-stage company developing novel regenerative therapies in ophthalmology, today announces it has entered into a new strategic partnership with Ora®, Inc. (“ORA”) the world’s leading, ophthalmic research organization, for the late-stage…
A Peptide Approach to Regenerative Medicine
Are regenerative peptides the answer to current challenges in the development of treatments for unmet needs? In an article published in PharmaTimes Magazine, Frank Lee, CSO, and Maria Chen, VP of Business Development, discuss the potential of pigment epithelium-derived factor…
Overcoming Challenges to Provide Affordable Treatments
Peptides and proteins have a wide range of therapeutic uses. These options come, however, with their own advantages and limitations, which must be identified before selecting the right treatment. In an article published in European Biopharmaceutical Review, Maria Chen, VP…
Haishan Jang, BRIM CEO, reveals the biggest challenges of orphan drug development
In an article published in European Biopharmaceutical Review, Haishan Jang, BRIM Biotechnology CEO, reveals the biggest challenges of orphan drug development and the significant breakthroughs that are helping the Life Science industry’s pursuit of innovation. Read the interview to find…